Work

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-113519

Authors: Shaji K. Kumar, Alan Fu, Khalid Mezzi, Megan Braunlin, Christopher Kim, Karim Iskander, Ruben Niesvizky, Sundar Jagannath, Ralph Boccia, Noopur Raje

Institutions: Mayo Clinic, Amgen (United States), NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Icahn School of Medicine at Mount Sinai, Center for Cancers and Blood Disorders, Massachusetts General Hospital

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2909550999

Cites:

Cited by:

Related to: 10